Noteworthy Price Action: Could Horizon Pharma PLC See a Reversal After This Very Strong Session?

Noteworthy Price Action: Could Horizon Pharma PLC See a Reversal After This Very Strong Session?

The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! About 2.09M shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 12.70% since April 5, 2016 and is downtrending. It has underperformed by 14.66% the S&P500.
The move comes after 6 months positive chart setup for the $3.07B company. It was reported on Nov, 7 by We have $25.95 PT which if reached, will make NASDAQ:HZNP worth $1.63 billion more.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 19 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Jefferies reinitiated the stock with “Buy” rating in Monday, November 23 report. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has “Equal-Weight” rating given on Monday, July 11 by Morgan Stanley. The stock has “Outperform” rating given by BMO Capital Markets on Wednesday, June 29. Mizuho maintained the shares of HZNP in a report on Monday, December 14 with “Buy” rating. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, May 3. The firm has “Buy” rating by Goldman Sachs given on Thursday, December 17. The stock has “Buy” rating given by Goldman Sachs on Monday, June 6. As per Tuesday, August 9, the company rating was maintained by Citigroup. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, September 13. On Tuesday, January 19 the stock rating was initiated by Jefferies with “Buy”.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.21, from 1 in 2016Q1. The ratio improved, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
The Montana-based Davidson Advsrs has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Mycio Wealth Partners Limited Liability Corp last reported 0.02% of its portfolio in the stock. Quantitative Invest Ltd has invested 0.02% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Tiaa Cref Management Limited Liability Co holds 503,967 shares or 0.01% of its portfolio. Moreover, Amer has 0.02% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 13,876 shares. Moreover, National Bank Of Montreal Can has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 618,861 shares. Swiss National Bank & Trust accumulated 243,556 shares or 0.01% of the stock. Moreover, Kingdon Capital Management Ltd Company has 3.67% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 4.06M shares. Utd Advisers Ltd Liability Company accumulated 0.02% or 104,339 shares. Timessquare Mgmt holds 0.42% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 3.86M shares. Tower Capital Limited Liability Co (Trc) holds 1,095 shares or 0% of its portfolio. The Massachusetts-based Rhumbline Advisers has invested 0.01% in Horizon Pharma PLC (NASDAQ:HZNP). Wfg Advsrs Lp has 0.02% invested in the company for 5,551 shares. Silvercrest Asset Mngmt Grp Limited Liability Corporation has 0% invested in the company for 15,560 shares. Beach Point Management L P last reported 1.96M shares in the company.

Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 2 sales for $500,280 net activity. 2,900 shares with value of $58,000 were sold by SHERMAN JEFFREY W on Tuesday, August 2. $442,280 worth of Horizon Pharma PLC (NASDAQ:HZNP) was sold by Nohria Virinder.

More notable recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: which released: “Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!” on October 11, 2016, also with their article: “Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.” published on October 25, 2016, published: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” on November 03, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) were released by: and their article: “Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes” published on October 20, 2016 as well as‘s news article titled: “Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and …” with publication date: October 13, 2016.

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment